Fundraising FoxThe Column Group — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Judo Bio Co-Founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(Executive Chair and Acting CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesDroia VenturesYK Bioventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
Kimia is a therapeutics company developing new drugs through its ATLAS platform, working with partners in the pharmaceutical and biotechnology industries.
AI & Machine LearningBiotechDeep Tech
Stig Hansen(Founder)in
Co-investorsAirTree VenturesHorizons VenturesBlackbird VenturesDIMENSIONDimension CapitalSkip Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.